13C6-Glucose for Critical Illness
(TORCH-ICU Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to understand how cells of the immune system use the common sugar glucose during critical illness. Investigators will intravenously infuse a non-radioactive carbon-13 glucose tracer into adult intensive care unit (ICU) participants over a few hours and collect immune cells from the blood to track uptake and usage of this glucose within these immune cells.
Are You a Good Fit for This Trial?
This trial is for adults in the intensive care unit (ICU) with critical illnesses such as sepsis, autoimmune diseases, diabetes, or acute respiratory distress syndrome. Participants must be able to safely receive an intravenous infusion and have blood samples taken.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- 13C6-Glucose
Trial Overview
Researchers are giving a safe, non-radioactive form of glucose through an IV to ICU patients. They will then collect blood samples to see how immune cells use this special glucose during severe illness.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Participants will receive 10-25 grams of 13C6-glucose intravenously over 2-4 hours during a single ICU study procedure.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Vanderbilt University Medical Center
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.